Evidence map›Paper›PMID 33665346›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2021

Differential blood DNA methylation across Lewy body dementias.

Chanond A Nasamran, Anubhav Nikunj Singh Sachan, Jennifer Mott, Yuliya I Kuras, Clemens R Scherzer, Harvard Biomarkers Study, Eugenia Ricciardelli, Kristen Jepsen, Steven D Edland, Kathleen M Fisch and 1 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Differential blood DNA methylation across Lewy body dementias.Alzheimer's & dementia (Amsterdam, Netherlands) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Chanond A NasamranCenter for Computational Biology & Bioinformatics Department of Medicine University of California San Diego La Jolla California USA.
Anubhav Nikunj Singh SachanDivision of Biostatistics, Department of Family Medicine and Public Health University of California San Diego La Jolla California USA.
Jennifer MottDepartment of Neurosciences, School of Medicine University of California San Diego La Jolla California USA.
Yuliya I KurasCenter for Advanced Parkinson Research and Precision Neurology Program, Harvard Medical School Brigham & Women's Hospital Boston Massachusetts USA.
Clemens R ScherzerCenter for Advanced Parkinson Research and Precision Neurology Program, Harvard Medical School Brigham & Women's Hospital Boston Massachusetts USA.
Harvard Biomarkers StudyCenter for Computational Biology & Bioinformatics Department of Medicine University of California San Diego La Jolla California USA.
Eugenia RicciardelliGenomics Center Institute for Genomics Medicine University of California San Diego La Jolla California USA.
Kristen JepsenGenomics Center Institute for Genomics Medicine University of California San Diego La Jolla California USA.
Steven D EdlandDepartment of Neurosciences, School of Medicine University of California San Diego La Jolla California USA.
Kathleen M FischCenter for Computational Biology & Bioinformatics Department of Medicine University of California San Diego La Jolla California USA.
Paula DesplatsDepartment of Neurosciences, School of Medicine University of California San Diego La Jolla California USA.
University of California, San Diego · USBrigham and Women's Hospital · USHarvard University · USJoint Center for Structural Genomics · USUniversity of California System · US

Funding

National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 1985 to 2018
$42.1M
UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DOUGLAS R GALASKO · 2019 to 2026
$34.9M
NINDS Biomarker RepositoryU24NS095871 · NINDS · INDIANA UNIVERSITY INDIANAPOLIS · PI TATIANA M. FOROUD · 2015 to 2026
$18.3M
GBA pathway markers for Lewy body dementiasU01NS100603 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHERZER, CLEMENS R · 2016 to 2020
$2.9M
Biomarkers for early intervention in Parkinson diseaseU01NS082157 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHERZER, CLEMENS R · 2012 to 2016
$2.5M
Applying DNA methylation for differential diagnosis in Lewy Body DementiaR03NS104013 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DESPLATS, PAULA ALEJANDRA · 2017 to 2018
$155k
NCATS NIH HHS UL1 TR001442NIA NIH HHS P30 AG062429NIA NIH HHS P50 AG005134NIA NIH HHS U24 AG021886NINDS NIH HHS R03 NS104013NINDS NIH HHS U01 NS082157NINDS NIH HHS U01 NS100603NINDS NIH HHS U24 NS095871
6 · The paper itself

Abstract

introductionDementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are characterized by cognitive alterations, visual hallucinations, and motor impairment. Diagnosis is based on type and timing of clinical manifestations; however, determination of clinical subtypes is challenging. The utility of blood DNA methylation as a biomarker for Lewy body disorders (LBD) is mostly unexplored.

methodsWe performed a cross-sectional analysis of blood methylation in 42 DLB and 50 PDD cases applying linear models to compare groups and logistic least absolute shrinkage and selection operator regression to explore the discriminant power of methylation signals.

resultsDLB blood shows differential methylation compared to PDD. Some methylation changes associate with core features of LBD. Sets of probes show high predictive value to discriminate between variants. DISCUSSION: Our study is the first to explore LBD blood methylation. Despite overlapping clinical presentation, we detected differential epigenetic signatures that, if confirmed in independent cohorts, could be developed into useful biomarkers.

Indexed as

biomarkerbloodcognitive scoresdementiadementia with Lewy bodies (DLB)DNA methylationepigeneticsLewy body diseases (LBD)Parkinson's disease dementia (PDD)REM sleep behavior disorder (RBD)

Identifiers

PMID33665346
PMCPMC7896631
OpenAlexW3129892258

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.